title: Cinacalcet in peritoneal dialysis patients: one-center experience.
abstract: BACKGROUND
  Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet. Most studies were done only in hemodialysis patients, with few data from peritoneal dialysis patients.
  
  
  OBJECTIVE
  The aim of our work was to evaluate the effectiveness of cinacalcet in secondary hyperparathyroidism in a one-center peritoneal dialysis patients.
  
  
  METHODS
  A retrospective study was performed in 27 peritoneal dialysis patients with moderate to severe secondary hyperparathyroidism (PTHi > 500 pg/mL with normal or elevated serum calcium levels) treated with cinacalcet. Demographic, clinical and laboratory parameters at the beginning of cinacalcet therapy, second, fourth, sixth months after and at the time it was finished were analyzed.
  
  
  RESULTS
  Patients were under peritoneal dialysis at 30.99 ± 16.58 months and were treated with cinacalcet for 15.6 ± 13.4 months; 21 (77.8%) patients showed adverse gastrointestinal effects; PTHi levels at the beginning of cinacalcet therapy were 1145 ± 449 pg/mL. The last PTHi levels under cinacalcet therapy was 1131 ± 642 pg/mL. PTHi reduction was statistically significant at 2 months after the beginning of cinacalcet (p = 0.007) but not in the following evaluations.
  
  
  CONCLUSIONS
  It is necessary the development of new forms of cinacalcet presentation, in order to avoid gastrointestinal effects adverse factors and to improve therapeutic adherence.
authors.affiliation: Hospital de Santa Cruz, Brazil.
authors.forename: Sara Querido
authors.initials: SQ
authors.lastname: Conde
authors.affiliation: Hospital de Santa Cruz, Brazil.
authors.forename: Patrícia
authors.initials: P
authors.lastname: Branco
authors.affiliation: Hospital de Santa Cruz, Brazil.
authors.forename: Henrique
authors.initials: H
authors.lastname: Sousa
authors.affiliation: Hospital de Santa Cruz, Brazil.
authors.forename: Teresa
authors.initials: T
authors.lastname: Adragão
authors.affiliation: Hospital de Santa Cruz, Brazil.
authors.forename: Augusta
authors.initials: A
authors.lastname: Gaspar
authors.affiliation: Hospital de Santa Cruz, Brazil.
authors.forename: José Diogo
authors.initials: JD
authors.lastname: Barata
mesh_terms: D057966:Calcimimetic Agents / Q000627:therapeutic use*; D000069449:Cinacalcet / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D012189:Retrospective Studies
chemical_list: D057966:Calcimimetic Agents; D000069449:Cinacalcet